Detail akcie Trevi Therapeuti Rg online

Business Summary: Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Trevi Therapeutics Inc revenues was not reported. Net loss decreased 6% to $34.4M. Lower net loss reflects Pharmaceuticals segment loss increase of less than 1% to $39.1M. Basic Earnings per Share excluding Extraordinary Items increased from -$0.36 to -$0.26.